Search hospitals
>
New York
>
New York
Bellevue Hosp / New York Univ Med Ctr
Claim this profile
New York, New York 10016
Global Leader in HIV Infection
Global Leader in Human Immunodeficiency Virus Infection
Conducts research for AIDS
Conducts research for Opportunistic Infections
Conducts research for AIDS-Related Complex
196 reported clinical trials
10 medical researchers
Summary
Bellevue Hosp / New York Univ Med Ctr is a medical facility located in New York, New York. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, AIDS, Opportunistic Infections, AIDS-Related Complex and other specialties. Bellevue Hosp / New York Univ Med Ctr is involved with conducting 196 clinical trials across 226 conditions. There are 10 research doctors associated with this hospital, such as Nina Beri, MD, Maryann Kwa, MD, Violeta Popov, MD, and Renee Williams, MD.
Top PIs
Nina Beri, MD
Laura and Isaac Perlmutter Cancer Center at NYU Langone
8 years of reported clinical research
Maryann Kwa, MD
Laura and Isaac Perlmutter Cancer Center at NYU Langone
8 years of reported clinical research
Violeta Popov, MD
Manhattan VA Medical Center
4 years of reported clinical research
Renee Williams, MD
NYU Langone Health
4 years of reported clinical research
Clinical Trials running at Bellevue Hosp / New York Univ Med Ctr
Ovarian Cancer
Breast Cancer
Pulmonary Embolism
Focal Segmental Glomerulosclerosis
Diabetes
Type 1 Diabetes
Peritoneal Adenocarcinoma
Peritoneal Serous Adenocarcinoma
Fibroadenoma
Breast Fibroadenoma
Olaparib +/- Bevacizumab
for Ovarian Cancer
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.
Recruiting
2 awards
Phase 3
4 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Bellevue Hosp / New York Univ Med Ctr?
Bellevue Hosp / New York Univ Med Ctr is a medical facility located in New York, New York. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, AIDS, Opportunistic Infections, AIDS-Related Complex and other specialties. Bellevue Hosp / New York Univ Med Ctr is involved with conducting 196 clinical trials across 226 conditions. There are 10 research doctors associated with this hospital, such as Nina Beri, MD, Maryann Kwa, MD, Violeta Popov, MD, and Renee Williams, MD.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.